The following research projects were approved by Susan G. Komen's national Board of Directors for funding, and will be funded once the Grant Agreements between Komen and the Grantee institution(s) are fully-executed. There are 7 types (mechanisms) of grants: Career Catalyst Research (CCR), Graduate Training in Disparities Research (GTDR), Postdoctoral Fellowships (PDF), Komen Scholars Grants (KS), Scientific Advisory Board Grants (SAB), Opportunity Grants (OG), and Sponsored Programs and Partnerships (SPP). For more information on the scientific programs and partnerships that are supported by the Komen Research Program, see here.
| Select a column title to sort this information. Select a Project Title for detailed grant information. |
 |
Type to Search:
| Project Title | Investigators | Organization | State/ Country | Affiliate | Mechanism |
|---|---|---|---|---|---|
| Prioritizing adjuvant targeted therapy for TNBC patients via molecular profiling | Justin Balko,Pharm.D., Ph.D. | Vanderbilt University | TN | Greater Nashville Affiliate | CCR Basic and Translational |
| Targeting epithelial-stromal crosstalk networks in breast cancer | Andrew Beck, M.D. | Beth Israel Deaconess Medical Center | MA | Massachusetts Affiliate | CCR Basic and Translational |
| Characterization and targeted therapy of hormone-refractory breast cancer | Sarat Chandarlapaty, M.D., Ph.D. | Memorial Sloan-Kettering Cancer Center | NY | Greater New York City Affiliate | CCR Basic and Translational |
| Alterated ubiquitin signaling networks regulating breast cancer proliferation | Michael Emanuele, Ph.D. | The University of North Carolina at Chapel Hill | NC | North Carolina Triangle to Coast Affiliate | CCR Basic and Translational |
| How does circulating cholesterol promote breast cancer growth and metastasis? | Emily Gallagher, M.D. | Icahn School of Medicine at Mount Sinai | NY | Greater New York City Affiliate | CCR Basic and Translational |
| Targeted blockade of the inflammatory network in triple-negative breast cancer | Zachary Hartman, Ph.D. | Duke University Medical Center | NC | North Carolina Triangle to Coast Affiliate | CCR Basic and Translational |
| Mitochondrial phospho-proteomic and metabolic analyses of HER2+ breast cancer | Taro Hitosugi, Ph.D. | Mayo Clinic | MN | Minnesota Affiliate | CCR Basic and Translational |
| A structural framework for targeting the HER3 receptor in breast cancer | Natalia Jura, Ph.D. | University of California, San Francisco | CA | San Francisco Bay Affiliate | CCR Basic and Translational |
| Cancer mutations and prognosis in premenopausal, early-stage breast cancer | Sherene Loi, Ph.D. | The University of Melbourne | Australia | N/A | CCR Basic and Translational |
| The role of lncRNAs associated with neoadjuvant hormone therapy sensitivity | Christopher Maher, Ph.D. | Washington University in St.Louis | MO | St. Louis Affiliate | CCR Basic and Translational |
| Targeting the APOBEC3B-induced mutator phenotype in breast cancer prevention | Guang Peng, M.D., Ph.D. | University of Texas M.D. Anderson Cancer Center | TX | Houston Affiliate | CCR Basic and Translational |
| Glycosylation as a link between breast cancer metabolism and tumorigenesis | Matthew Pratt, Ph.D. | USC/University of Southern California | CA | Los Angeles County Affiliate | CCR Basic and Translational |
| The role of CAF-derived IGFBP-2 in preventing anoikis in breast cancer cells | Zachary Schafer, Ph.D. | University of Notre Dame | IN | Northern Indiana Affiliate | CCR Basic and Translational |
| Endocrine therapy resistance of ER+ breast cancer caused by ESR1 gene aberrations | Jieya Shao, Ph.D. | Washington University in St.Louis | MO | St. Louis Affiliate | CCR Basic and Translational |
| A nanoparticle-based HER2 breast cancer vaccine | Nicole Steinmetz, Ph.D. | Case Western Reserve University | OH | Northeast Ohio Affiliate | CCR Basic and Translational |
| A novel protein complex controls homologous recombination repair in breast cancer | Jingsong Yuan, M.D., Ph.D. | University of Texas M.D. Anderson Cancer Center | TX | Houston Affiliate | CCR Basic and Translational |
| Therapeutic strategies to restore the immunosurveillance against breast cancer | Xiang Zhang, Ph.D. | Baylor College of Medicine | TX | Houston Affiliate | CCR Basic and Translational |
| Improving how we predict toxicity for older women with breast cancer | Rachel Freedman, M.D. | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | CCR Clinical |
| A trial of endocrine response in patients with invasive lobular carcinoma | Rachel Jankowitz, M.D. | University of Pittsburgh | PA | Pittsburgh Affiliate | CCR Clinical |
| Application of lipidomics to a sulindac intervention of pain | Jessica Miller, Ph.D. | University of Arizona | AZ | Southern Arizona Affiliate | CCR Clinical |
| Epigenetic memory of breast cancer treatment-induced inflammation and fatigue | Mylin Torres, M.D. | Emory University | GA | Greater Atlanta Affiliate | CCR Clinical |
| Susan G. Komen graduate training in breast cancer disparities at UC Berkeley | Joan Bloom, Ph.D.; Mahasin Mujahid, Ph.D. | University of California, Berkeley | CA | San Francisco Bay Affiliate | Graduate Training in Disparities Research Grants |
| Breast cancer disparities among low income women | Cathy Bradley, Ph.D. | Virginia Commonwealth University | VA | Central Virginia Affiliate | Graduate Training in Disparities Research Grants |
| Multidisciplinary training in the biology of breast cancer disparities | Michele Cote, Ph.D.; Manohar Ratnam, Ph.D. | Wayne State University | MI | Komen Detroit Race for the Cure | Graduate Training in Disparities Research Grants |
| Graduate training program in breast cancer disparities at UTSPH | Sally Vernon, Ph.D. | University of Texas Health Science Center at Houston | TX | Houston Affiliate | Graduate Training in Disparities Research Grants |
| UIC Komen breast cancer disparities fellowship | Garth Rauscher, Ph.D. | University of Illinois - Chicago | IL | Chicagoland Area Affiliate | Graduate Training in Disparities Research Grants |
| UNC-CIDRZ Proposal to Conduct a Comprehensive
Assessment of Current Breast and Cervical Cancer Control in Zambia |
Groesbeck Parham | The University of North Carolina at Chapel Hill | NC | North Carolina Triangle to Coast Affiliate | GSP |
| BHGI International Learning Laboratories | Benjamin Anderson, M.D. | Fred Hutchinson Cancer Research Center | WA | Puget Sound Affiliate | Komen Scholars |
| Establishing novel therapeutic approaches for breast cancer | Alan Ashworth, Ph.D. | Institute of Cancer Research | Great Britain | NA | Komen Scholars |
| Predictive factors of recurrences and distant metastases in ER+ breast cancer | Sunil Badve, M.D. | Indiana University | IN | Central Indiana Affiliate | Komen Scholars |
| Profiling of Metastatic Triple Negative Breast Cancer | Kimberly Blackwell, M.D. | Duke University | NC | North Carolina Triangle to Coast Affiliate | Komen Scholars |
| Biomechanical profiling as a biomarker for breast cancer progression | Gerard Blobe, M.D., Ph.D. | Duke University | NC | North Carolina Triangle to Coast Affiliate | Komen Scholars |
| Breast cancer risk assessment using copy number variation | Melissa L. Bondy, Ph.D. | Baylor College of Medicine | TX | Houston Affiliate | Komen Scholars |
| Analysis of the Integration of Cell-Cell Adhesion & Yap Networks Regulating Tumor Growth & Invasion | Joan Brugge, Ph.D. | Harvard Medical School | MA | Massachusetts Affiliate | Komen Scholars |
| Translating biology into therapeutic advances | Lisa Carey, M.D. | University of North Carolina at Chapel Hill | NC | North Carolina Triangle to Coast Affiliate | Komen Scholars |
| Early phase clinical trials of targeted therapy for metastatic breast cancer | Claire Dees, M.D. | University of North Carolina at Chapel Hill | NC | North Carolina Triangle to Coast Affiliate | Komen Scholars |
| Efficacy Of DNA damaging and non-damaging regimens according to molecular subtypes defined on CTCs | Angelo DiLeo, M.D., Ph.D. | Sandro Pitigliani Medical Oncology Unit | Italy | Susan G. Komen Italia | Komen Scholars |
| Impact of risk-reducing salpingo-oophorectomy on non-cancer outcomes in high risk women | Susan Domchek, M.D. | University of Pennsylvania | PA | Philadelphia Affiliate | Komen Scholars |
| Mechanisms of Endocrine Resistance in Estrogen Receptor Positive Breast Cancer | Matthew Ellis, Ph.D. | Baylor College of Medicine | TX | Houston Affiliate | Komen Scholars |
| Development of biomarkers of response to prevention interventions with lignans | Carol Fabian, M.D. | University of Kansas Medical Center Research Institute | KS | Greater Kansas City Affiliate |
Komen Scholars |
| Hereditary breast cancer: cause and effect | William Foulkes, M.D., Ph.D. | McGill University | Canada | NA | Komen Scholars |
| Stress reduction in breast cancer survivors: intervention development and evaluation | Patricia Ganz, M.D. | University of California, Los Angeles | CA | Los Angeles County Affiliate | Komen Scholars |
| Exploratory Study of Immune Cells in Breast Cancer | Judy Garber, M.D. | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | Komen Scholars |
| Predictors of bone metastasis in breast cancer | Julie Gralow, M.D. | University of Washington School of Medicine Alliance | WA | Puget Sound Affiliate | Komen Scholars |
| Microenvironmental and epigenomic mechanisms of therapeutic resistance | Joe Gray, Ph.D. | Oregon Health & Science University | OR | Oregon and SW Washington Affiliate |
Komen Scholars |
| Muscle Weakness Associated with Breast Cancer Bone Metastases | Theresa Guise, M.D. | Indiana University | IN | Central Indiana Affiliate | Komen Scholars |
| Using breast tissue expression patterns to inform our understanding of breast cancer risk factors | Susan Hankinson, Sc.D. | Brigham and Women's Hospital and Harvard Medical School | MA | Massachusetts Affiliate | Komen Scholars |
| Biomarker studies for personalized breast cancer care | Daniel Hayes, M.D. | University of Michigan | MI | Mid-Michigan Affiliate |
Komen Scholars |
| Reversion of triple-negative breast cancer: insights to new targeted therapy | Mien-Chie Hung, Ph.D. | UT M.D. Anderson Cancer Center | TX | Houston Affiliate | Komen Scholars |
| MR imaging phenotypes of breast cancer | Nola Hylton, Ph.D. | University of California, San Francisco | CA | San Francisco Bay Affiliate | Komen Scholars |
| Uncovering mechanisms contributing to metastasis and to drug resistance in breast cancer | Nancy Hynes, Ph.D. | Friedrich Miescher Institute for Biomedical Research | Switzerland | NA | Komen Scholars |
| Mechanisms of endocrine action: ER-induced apoptosis and HRT-associated breast cancer | V. Craig Jordan, Ph.D., D. Sc. | UT M.D. Anderson Cancer Center | TX | Houston Affiliate | Komen Scholars |
| Molecular and clinical characterization of breast cancer heterogeneity in Israel | Bella Kaufman, M.D. | Chaim Sheba Medical Center | Israel | NA | Komen Scholars |
| Identification of new genes for inherited breast cancer by application of next generation sequencing in high-risk families | Mary-Claire King, Ph.D. | University of Washington | WA | Puget Sound Affiliate | Komen Scholars |
| Elucidating Novel Mechanisms of Resistance to HER2-Directed Therapy | Ian Krop, M.D., Ph.D. | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | Komen Scholars |
| Understanding and targeting IGF's role in G2/M progression | Adrian Lee, Ph.D. | University of Pittsburgh | PA | Pittsburgh Affiliate | Komen Scholars |
| Mechanism by which BRCA1 elicits a state of mammary epithelial differentiation control | David Livingston, M.D. | Dana-Farber Cancer Institute and Harvard Medical School | MA | Massachusetts Affiliate | Komen Scholars |
| Optimizing Akt/mTOR targeted breast cancer therapy | Funda Meric-Bernstam, M.D., Ph.D. | UT M.D. Anderson Cancer Center | TX | Houston Affiliate | Komen Scholars |
| PARP inhibition after pre-operative chemotherapy | Kathy Miller, M.D. | Indiana University | IN | Central Indiana Affiliate | Komen Scholars |
| Combinatorial adaptive resistance therapy in breast cancer | Gordon Mills, M.D., Ph.D. | UT M.D. Anderson Cancer Center | TX | Houston Affiliate | Komen Scholars |
| Estrogen receptor-positive breast cancer recurrence through dependence receptor pathway | Harikrishna Nakshatri, Ph.D., D.V.M. | Indiana University | IN | Central Indiana Affiliate | Komen Scholars |
| Translating Breast Cancer Genomics In The Clinic | Olunfunmilayo Olopade, M.D. | University of Chicago | IL | Chicagoland Area Affiliate | Komen Scholars |
| Interplay between SRC-3, TRAF4 and ERK3 in breast cancers | Bert O’Malley, M.D. | Baylor College of Medicine | TX | Houston Affiliate | Komen Scholars |
| Biological consequences of novel PTEN pathway signaling defects in breast cancer | Ramon Parsons, M.D., Ph.D. | Icahn School of Medicine at Mount Sinai | NY | Greater New York City Affiliate | Komen Scholars |
| Breast cancer in young women | Ann Partridge, M.D. | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | Komen Scholars |
| Identification and education of low-income women at risk for hereditary breast cancer | Rena Pasick, Dr.PH. | University of California, San Francisco | CA | San Francisco Bay Affiliate | Komen Scholars |
| Breast cancer cell sensitivity to radiotherapy in the presence of PARP inhibitors | Lori Pierce, M.D. | University of Michigan | MI | Mid-Michigan Affiliate | Komen Scholars |
| Triple negative breast cancer: subtypes, molecular targets, and therapeutic approaches | Jennifer Pietenpol, Ph.D. | Vanderbilt University | TN | Greater Nashville Affiliate | Komen Scholars |
| Plk2 function in mammary gland development and breast cancer | Jeffrey Rosen, Ph.D. | Baylor College of Medicine | TX | Houston Affiliate | Komen Scholars |
| Genomic predictors of chemotherapy-induced toxicity | Brian Schneider, M.D. | Indiana University | IN | Central Indiana Affiliate | Komen Scholars |
| Mutational Landscape of Invasive Lobular Breast Cancer | Christos Sotiriou, M.D., Ph.D. | Jules Bordet Institute | Belgium | NA | Komen Scholars |
| Overcoming or preventing resistance to HER2 targeted therapies | Neil Spector, M.D. | Duke University School of Medicine | NC | North Carolina Triangle to Coast Affiliate | Komen Scholars |
| Phase II study of 5-azacytidine and entinostat (MS-275) in patients with advanced breast cancer | Vered Stearns, M.D. | Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine | MD | Komen Scholars | |
| Validation and implementation of genomic testing for chemotherapy and endocrine sensitivity | William Symmans, M.D. | UT M.D. Anderson Cancer Center | TX | Houston Affiliate | Komen Scholars |
| Mammary stem cells and breast cancer | Geoffrey Wahl, Ph.D. | The Salk Institute for Biological Studies | CA | San Diego Affiliate | Komen Scholars |
| Regulation of metastasis by mitochondrial DNA | Daniel Welch, Ph.D. | University of Kansas Medical Center Research Institute | KS | Greater Kansas City Affiliate | Komen Scholars |
| MRI guided preoperative partial breast irradiation in early stage breast cancer | Julia White, M.D. | Ohio State University | OH | Columbus | Komen Scholars |
| Johns Hopkins breast cancer program longitudinal repository | Antonio Wolff, M.D. | Johns Hopkins University | MD | Komen Scholars | |
| Identifying translational regulated genes activated by insulin-like growth factor signaling | Douglas Yee, M.D. | University of Minnesota, Masonic Cancer Center | MN | Minnesota Affiliate | Komen Scholars |
| Carolina Breast Cancer Study | Shelton Earp, M.D.; Shelley Hwang, M.D. | University of North Carolina at Chapel Hill | NC | North Carolina Triangle to Coast Affiliate | Opportunity Grants |
| Randomized phase II trial of neoadjuvant cisplatin vs doxorubicin/ cyclophosphamide (“AC”) in women with newly diagnosed breast cancer and germline BRCA mutation | Nadine Tung, M.D.; Judy Garber, M.D. | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | Opportunity Grants |
| Investigation of ILF2 as a novel breast cancer therapeutic target | Jessica Bockhorn, Ph.D.; Mark Pegram, M.D. (Mentor) | Stanford University | CA | San Francisco Bay Affiliate | PDF Basic and Translational |
| Targeting the cell cycle in sporadic & BRCA mutant triple negative breast cancer | Jason Carey, Ph.D.; Khandan Keyomarsi, Ph.D. (Mentor) | Unviersity of Texas M.D. Anderson | TX | Houston Affiliate | PDF Basic and Translational |
| Targeting metabolic pathways to circumvent endocrine resistance in breast cancer | Subhamoy Dasgupta, Ph.D.; Bert O'Malley, M.D. (Mentor) | Baylor College of Medicine | TX | Houston Affiliate | PDF Basic and Translational |
| Determining mechanisms of RON kinase signaling in breast cancer metastasis | Najme Faham, Ph.D.; Alana Welm, Ph.D. (Mentor) | Oklahoma Medical Research Foundation | OK | Oklahoma City | PDF Basic and Translational |
| Determining the role of somatic mutations in SERM-resistant breast cancers | Sean Fanning, Ph.D.; Geoffrey Greene, Ph.D. (Mentor) | University of Chicago | IL | Chicagoland Area Affiliate | PDF Basic and Translational |
| Global cell characterization of the BRCA1 interactome using the NEDDylator | Sean Hudson, Ph.D.; James Wells, Ph.D. (Mentor) | University of California, San Francisco | CA | San Francisco Bay Affiliate | PDF Basic and Translational |
| Radiographic-histological correlates of dense breast tissue | Brad Keller, Ph.D.; Despina Kontos, Ph.D. (Mentor) Michael Feldman, M.D., Ph.D. (Co-Mentor) | University of Pennsylvania | PA | Philadelphia Affiliate | PDF Basic and Translational |
| Interrogating the function of the oncogene TLOC1 in breast cancer | Ji Li, Ph.D.; William Hahn, M.D., Ph.D. (Mentor) | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | PDF Basic and Translational |
| Mechanism of PARP inhibitor in breast cancer therapy | Mo Li, Ph.D.; Xiaochun Yu, M.D., Ph.D. (Mentor) | The University of Michigan | MI | Mid-Michigan Affiliate | PDF Basic and Translational |
| How does Loss of the INPP4B affect breast cancer etiology and treatment outcomes? | Hui Liu, Ph.D.; Gerburg Wulf, M.D., Ph.D. (Mentor); Lewis Cantley, Ph.D. (Co-Mentor) | Beth Israel Deaconess Medical Center | MA | Massachusetts Affiliate | PDF Basic and Translational |
| Novel anti-metastamiR therapy for metastatic breast cancer | Rebecca Marquez, Ph.D.; Liang Xu, M.D., Ph.D. (Mentor); Danny Welch, Ph.D. (Co-Mentor) | University of Kansas Center for Research | KS | Greater Kansas City Affiliate | PDF Basic and Translational |
| Translating lobular breast cancer ‘omics’ to improved patients outcome | Otto Metzger, M.D.; Eric Winer, M.D. (Mentor) | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | PDF Basic and Translational |
| A novel therapeutic and diagnostic target in triple negative breast cancers | Krishna Midde, Ph.D.; Pradipta Ghosh, M.D. (Mentor); Marilyn Farquhar, Ph.D. (Co-Mentor) | University of California, San Diego | CA | San Diego Affiliate | PDF Basic and Translational |
| Targeting DNA damage responses in breast cancer | Kareem Mohni, Ph.D.; David Cortez, Ph.D. (Mentor) | Vanderbilt University Medical Center | TN | Greater Nashville Affiliate | PDF Basic and Translational |
| LTBP1: A prometastatic factor linking pregnancy to breast cancer | Carrie Oliver, Ph.D.; Pamela Cowin, Ph.D. (Mentor) | New York University School of Medicine | NY | Greater New York City Affiliate | PDF Basic and Translational |
| Development of selective Grp94 inhibitors for the treatment of breast cancer | Hardik Patel, Ph.D.; Gabriela Chiosis, Ph.D. (Mentor); Shanu Modi, M.D. (Co-Mentor) | Memorial Sloan-Kettering Cancer Center | NY | Greater New York City Affiliate | PDF Basic and Translational |
| Drivers and therapeutic targets in mucinous carcinomas of the breast | Salvatore Piscuoglio, Ph.D.; Britta Weigelt, Ph.D. (Mentor) | Memorial Sloan-Kettering Cancer Center | NY | Greater New York City Affiliate | PDF Basic and Translational |
| Improving response to radio and chemotherapy in triple-negative breast cancer | Giorgio Seano, Ph.D.; Rakesh Jain, Ph.D. (Mentor) | Massachusetts General Hospital | MA | Massachusetts Affiliate | PDF Basic and Translational |
| BET bromodomain proteins as novel therapeutic targets in TNBC | Shaokun Shu, Ph.D.; Kornelia Polyak, M.D., Ph.D. (Mentor) | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | PDF Basic and Translational |
| Harnessing altered ER turnover in invasive lobular carcinoma for improved therapy | Sreeja Sreekumar, Ph.D.; Steffi Oesterreich, Ph.D. (Mentor) | University of Pittsburgh | PA | Pittsburgh Affiliate | PDF Basic and Translational |
| Tracking intratumor heterogeneity in triple negative breast cancer | Daniel Stover, M.D.; Joan Brugge, Ph.D. (Mentor); Eric Winer, M.D. (Co-Mentor) | Harvard Medical School | MA | Massachusetts Affiliate | PDF Basic and Translational |
| Re-targeting virus-specific CD8+ T cells to recognize and attack breast tumors | Kwame Twumasi-Boateng, Ph.D.; Brad Nelson, Ph.D. (Mentor) | British Columbia Cancer Agency Branch | Canada | PDF Basic and Translational | |
| Optimization of calcification imaging in digital breast tomosynthesis | Raymond Acciavatti, Ph.D.; Emily Conant, M.D. (Mentor); Andrew Maidment, Ph.D. (Co-Mentor) | University of Pennsylvania | PA | Philadelphia Affiliate | PDF Clinical |
| Identification of phosphatases for the treatment of ER-negative breast cancer | Powel Brown, M.D., Ph.D. | UT MD Anderson | TX | Houston Affiliate | SAB Grants |
| Increasing Access of Latinas into Breast Cancer Clinical Trials | Amelie Ramirez, Ph.D. | UT Health Science Center at San Antonio | TX | San Antonio Affiliate | SAB Grants |
| Examination of the human kinome for novel genome-specific therapeutic targets in triple-negative breast cancer (TNBC) | George Sledge, M.D. | Stanford University | CA | San Francisco Bay Affiliate | SAB Grants |
| Clinical trials for HER2+ breast cancer | Eric Winer, M.D. | Dana-Farber Cancer Institute | MA | Massachusetts Affiliate | SAB Grants |
| Scientific travel award for breast cancer researcher to attend Obesity Society’s Annual Scientific Meeting 2013 | Derek Huffman, Ph.D. | Obesity Week, LLC | SPP | ||
| 2014 Accelerating Anticancer Agent Development and Validation Workshop | H. Kim Lyerly, M.D. | Duke University | NC | North Carolina Triangle to Coast Affiliate | SPP |
| Evidence Based Consensus Conference on Margins in DCIS Treated With and Without Radiotherapy | Monica Morrow, M.D. | Society of Surgical Oncology | SPP | ||
| Advocates in Science Educational Program at ASCO Breast Cancer Symposium 2014 | Elda Railey | Research Advocacy Network | SPP | ||
| Conference Sponsorship for AACR FY14 Programming | Michael Stewart | American Association for Cancer Research (AACR) | SPP | ||
| 2014 AACR Annual Meeting | Michael Stewart | American Association for Cancer Research (AACR) | SPP | ||
| IMPAKT 2014 | Nikolaj Tomma | European Society for Medical Oncology | SPP | ||
| Breast Cancer in Young Women (BCY2) Conference 2014 – Dublin, Ireland | Roberta Ventura | European School of Oncology | SPP | ||
| Society of Surgical Oncology 67th Annual Cancer Symposium | Eileen Widmer | Society of Surgical Oncology | SPP |